TY - JOUR
T1 - Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus
AU - Nandish, Shailesh
AU - Wyatt, Jamison
AU - Bailon, Oscar
AU - Smith, Mike
AU - Oliveros, Rene
AU - Chilton, Robert
N1 - Funding Information:
Publication of this supplement was supported by funding from Novo Nordisk. Editorial support was provided by Dr. Ruth Kleinpell and Mary Lou Briglio.
PY - 2011/8/2
Y1 - 2011/8/2
N2 - The role of cardiovascular risk reduction in patients with diabetes mellitus is significant as several factors have been found to promote accelerated atherosclerosis in persons with diabetes including hyperglycemia-induced endothelial dysfunction, impaired fibrinolysis, increased platelet aggregation, plaque instability, dysfunctional arterial remodeling, and fibrotic and calcified coronary arteries. Recent attention has focused on identifying a cardiovascular biomarker that would propose a better noninvasive way to detect or visualize subclinical cardiovascular disease and prevent cardiovascular events. This article reviews the use of commonly used cardiovascular risk assessment tools and emerging biomarkers including coronary artery calcium scanning, metabolomics, genomics, and the role of optimal revascularization and risk reduction strategies and their impact on reducing risk in patients with cardiovascular disease and diabetes.
AB - The role of cardiovascular risk reduction in patients with diabetes mellitus is significant as several factors have been found to promote accelerated atherosclerosis in persons with diabetes including hyperglycemia-induced endothelial dysfunction, impaired fibrinolysis, increased platelet aggregation, plaque instability, dysfunctional arterial remodeling, and fibrotic and calcified coronary arteries. Recent attention has focused on identifying a cardiovascular biomarker that would propose a better noninvasive way to detect or visualize subclinical cardiovascular disease and prevent cardiovascular events. This article reviews the use of commonly used cardiovascular risk assessment tools and emerging biomarkers including coronary artery calcium scanning, metabolomics, genomics, and the role of optimal revascularization and risk reduction strategies and their impact on reducing risk in patients with cardiovascular disease and diabetes.
UR - http://www.scopus.com/inward/record.url?scp=79961057159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79961057159&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2011.03.015
DO - 10.1016/j.amjcard.2011.03.015
M3 - Review article
C2 - 21802580
AN - SCOPUS:79961057159
SN - 0002-9149
VL - 108
SP - 42B-51B
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 3 SUPPL.
ER -